Successful use of radiopharmaceuticals in localization of diseased tissue drives carrier based diagnostic agents for oncology, i.e. in colorectal cancer, breast cancer, neuroendocrine tumor, small-cell lung cancer, prostate cancer and cardiovascular diseases.
Over 10,000 hospitals world wide use radioisotopes for in-vivo diagnosis or treatment reaching 35 million patients each year. There is a growing potential of radio-therapeutic products and the concomitant technological advancements will continuously drive the demand for radiopharmaceuticals.
The ideal cancer imaging tool is a homogenous conjugate with a defined payload-carrier ratio that allows specific tumor targeting of the payload with minimal side-effects and fast turnover. Antibody Radio Conjugates (ARCs) are complex to produce and suffer from a number of other disadvantages such as non-specific conjugation, heterogeneous isotope-to-antibody ratios, and long residence times in the circulation and non-tumor tissues.
These disadvantages of ARCs are addressed by Affilin® Radio Conjugates as they enable site-specific conjugation of isotope-loaded chelators to yield a homogenous therapeutic product with defined isotope-to-carrier ratio. At the same time, half-life can be adjusted to balance sufficient tumor residence time with a minimum duration in the circulation to maximize contrast and reduce the risk of side effects. Thus, Affilin® Radio Conjugates offer the potential to significantly improve diagnostic and therapeutic performance.